Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Andrzej Panek"'
Publikováno v:
Vaccines, Vol 12, Iss 5, p 471 (2024)
This study follows 99 subjects vaccinated with Pfizer/BioNTech COVID-19 vaccines over two years, with particular focus on the last year of observation (between days 360 and 720). The response to the vaccination was assessed with Diasorin’s SARS-CoV
Externí odkaz:
https://doaj.org/article/3cb6ee28e7ca4fb48f775a6f857902bd
Autor:
Jakub Swadźba, Tomasz Anyszek, Andrzej Panek, Agnieszka Chojęta, Anna Piotrowska-Mietelska, Emilia Martin
Publikováno v:
Vaccines, Vol 11, Iss 2, p 278 (2023)
This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a year, with particular focus on the influence of a booster shot administered around 10 months after the primary immunization. The response to the vacc
Externí odkaz:
https://doaj.org/article/334fa9cc886e4d2487271eb8979185fa
Autor:
Jakub Swadźba, Maciej Bednarczyk, Tomasz Anyszek, Danuta Kozlowska, Andrzej Panek, Emilia Martin
Publikováno v:
Practical Laboratory Medicine, Vol 25, Iss , Pp e00212- (2021)
Objectives: This study was aimed at providing some insights into the real-life performance of the commercial, clinically validated anti-SARS-CoV-2 antibody assays. Methods: The residual, anonymized samples from 97 patients referred for anti-SARS-CoV-
Externí odkaz:
https://doaj.org/article/63ac796d43b44632a604a7a6207a89a7
Autor:
Jakub Swadźba, Tomasz Anyszek, Andrzej Panek, Agnieszka Chojęta, Kinga Wyrzykowska, Emilia Martin
Publikováno v:
Diagnostics, Vol 12, Iss 6, p 1426 (2022)
The immunoassays used to measure anti-spike SARS-CoV-2 antibodies are widely available on the market. However, their performance in COVID-19 vaccinees is not yet adequately assessed. Our study provides a head-to-head comparison of five methods: Abbot
Externí odkaz:
https://doaj.org/article/7aa9a235a1d247b0aea18a2fc5289992
Publikováno v:
Vaccines, Vol 9, Iss 11, p 1367 (2021)
We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred su
Externí odkaz:
https://doaj.org/article/81d9d99ff95c4f208db17f815b29de2e
Autor:
Tomasz Anyszek, Andrzej Panek, Jakub Swadźba, Maciej Bednarczyk, Emilia Martin, Danuta Kozlowska
Publikováno v:
Practical Laboratory Medicine, Vol 25, Iss, Pp e00212-(2021)
Practical Laboratory Medicine
Practical Laboratory Medicine
Objectives This study was aimed at providing some insights into the real-life performance of the commercial, clinically validated anti-SARS-CoV-2 antibody assays. Methods The residual, anonymized samples from 97 patients referred for anti-SARS-CoV-2
Publikováno v:
Vaccines, Vol 9, Iss 1367, p 1367 (2021)
Vaccines
Volume 9
Issue 11
Vaccines
Volume 9
Issue 11
We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred su
Publikováno v:
Scientific Journals of Rzeszów University of Technology, Series: Electrotechnics. :171-180